In a bid to make bulk drugs for cardiac, anti-infectives, anti-tuberculosis, neurology and other segments, Lupin is reportedly planning to expand its Vadodara facility. In this regard, the company will invest around Rs 270 crore.
The Dabhasa plant of Lupin near Vadodara is one of the leading bulk drug manufacturing sites for the company. The Dabhasa plant is one of our major active pharmaceutical ingredient manufacturing sites which also exports. It is a US Food and Drug Administration (USFDA) approved facility.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
